好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Leprosy in two patients with Relapsing Remitting Multiple Sclerosis (RRMS) treated with Fingolimod
Multiple Sclerosis
P4 - Poster Session 4 (5:30 PM-6:30 PM)
15-012
To describe two patients who acquired leprosy while being treated with Fingolimod for RRMS. 

Leprosy (Hansen’s disease) is a chronic infection caused by Mycobacterium leprae. The disease develops over months to years and may cause extensive damage to the skin and peripheral nervous system. In Multiple Sclerosis (MS), Fingolimod treatment is known to increase the risk for infections. There is one prior reported case of leprosy while on Fingolimod for RRMS. We report two further cases of leprosy in patients with RRMS and treated with Fingolimod.
Retrospective chart review of patient records of individuals with MS treated with Fingolimod, followed at the Maxine Mesinger Multiple Sclerosis Clinic at Baylor College of Medicine, Houston, TX, USA.
Two female patients [63 (P1) and 71 (P2) years old] with a diagnosis of leprosy were identified. The diagnosis was made via skin biopsy and the mean time of diagnosis from the initiation of Fingolimod was 34.5 months. P1’s absolute lymphocyte count (ALC) was 451 seven months prior to the diagnosis. P2’s ALC was 118 two months prior to the diagnosis. Both patients were potentially exposed to armadillo feces. They were placed on triple antibiotic therapy and were continued on Fingolimod without any complications.
Here we report two additional patients with RRMS diagnosed with leprosy while on Fingolimod. The exact cause and effects between Fingolimod and leprosy is unclear at this time; however, the patients have had a low ALC around the diagnosis and were identified to have a history of potential exposure.
Authors/Disclosures
Alfred Balasa, MD
PRESENTER 		Dr. Balasa has nothing to disclose.
George J. Hutton, MD, FAAN (Baylor College of Medicine) Dr. Hutton has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Autoimmunity Biologic Solutions, Inc.. The institution of Dr. Hutton has received research support from Biogen. The institution of Dr. Hutton has received research support from Genentech. The institution of Dr. Hutton has received research support from Genzyme.